Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR) announced that Bassil Dahiyat, Ph.D., president and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Xencor is a clinical-stage biopharmaceutical company developing antibodies and cytokines for cancer and autoimmune diseases. The presentation will be available via webcast and archived for 30 days.
01/03/2024 - 04:01 PM
PASADENA, Calif. --(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 3:45 p.m. PST.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com . After the webcast, a replay will be archived on the website for at least 30 days.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103100031/en/
Charles Liles
cliles@xencor.com
Source: Xencor, Inc.
The conference is on January 10, 2024.
The ticker symbol is XNCR.
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for cancer and autoimmune diseases.
The presentation will be available via webcast in the Investors section of the Company's website at www.xencor.com.
The replay will be archived on the website for at least 30 days.
XNCR Rankings
#4337 Ranked by Stock Gains
XNCR Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Monrovia
About XNCR
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
